Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndromeClinical Trial Published on 2021-09-072022-10-05 Journal: Revista de la Facultad de Ciencias Médicas (Córd [Category] 임상, [키워드] according to protocol acute respiratory syndrome added Admission Adult anti-inflammatory effect caused circulating cytokines clinical study coronavirus Coronavirus infections COVID-19 COVID-19 patients COVID-19 pneumonia patient Critical determine distress Effect Efficacy and safety elevated English Host ill patient immune response intensive care Janus kinase Janus kinase inhibitors lower mortality mechanical ventilation multicenter Open-label organ injury Patient patients patients with COVID-19 Phase 2 study primary endpoint prospectivo receiving reduction reported Respiratory distress syndrome Result ruxolitinib ruxolitinib dose side Spanish Standard of care study drug Toxicity Treatment [DOI] 10.31053/1853.0605.v78.n3.32800 PMC 바로가기 [Article Type] Clinical Trial
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritisSupplement Published on 2021-05-052024-09-04 Journal: Rheumatology (Oxford, England) [Category] 대상포진, [키워드] filgotinib itacitinib Janus kinase inhibitors rheumatoid arthritis Treatment Upadacitinib [DOI] 10.1093/rheumatology/keaa893 PMC 바로가기 [Article Type] Supplement
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the PandemicPharmacology Published on 2020-12-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory distress acute respiratory syndrome biologic agent caused Clinical outcome colony stimulating factor Comprehensive coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patients cytokine death detrimental disease disease modifying anti-rheumatic drug DMARDs (biologic) drug Efficacy and safety Evidence hyper-inflammatory immune response IL-6 immunesuppressants IMPROVE include Inflammation inflammatory condition inhibiting inhibitor jak inhibitors Janus kinase inhibitors monoclonal antibody Necrosis observational study patients peak pharmacological randomized clinical trials receptor repurposing review sarilumab SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 syndrome synthetic therapeutic option therapeutic strategy tissue damage Tocilizumab Treatment [DOI] 10.3389/fphar.2020.598308 PMC 바로가기 [Article Type] Pharmacology
Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK InhibitorsArticle Published on 2020-10-202024-09-02 Journal: International Journal of Molecular Sciences [Category] 대상포진, [키워드] interferon signature Janus kinase inhibitors juvenile idiopathic arthritis juvenile systemic erythematosus lupus juvenile systemic sclerosis monogenic interferonopathies off-label medications Pediatric rheumatology transcriptomics [DOI] 10.3390/ijms21207767 PMC 바로가기 [Article Type] Article
COVID-19 and the newly rediscovered multidisciplinarityForeword Published on 2020-09-222022-10-31 Journal: Immunotherapy [Category] Coronavirus, MERS, SARS, [키워드] anti-PD-1/PD-L1 COVID-19 Immunosuppressed Immunotherapy Janus kinase inhibitors pandemic SARS-CoV-2 Tocilizumab virus [DOI] 10.2217/imt-2020-0205 PMC 바로가기 [Article Type] Foreword
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel DiseaseSupplement Article Published on 2020-08-112024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] inflammatory bowel diseases Janus kinase inhibitors Janus kinases Signal transducer and activator of transcription [DOI] 10.1093/ecco-jcc/jjaa014 PMC 바로가기 [Article Type] Supplement Article
Is tofacitinib a game-changing drug for ulcerative colitis?Review Article Published on 2020-06-182024-09-04 Journal: United European gastroenterology journal [Category] 대상포진, [키워드] Case report Inflammatory bowel disease Janus kinase inhibitors Tofacitinib ulcerative colitis [DOI] 10.1177/2050640620935732 PMC 바로가기 [Article Type] Review Article
COVID‐19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statementReview Article Published on 2020-05-032023-06-16 Journal: The Australasian journal of dermatology [Category] MERS, SARS, [키워드] biologic agents biologics Ciclosporin COVID‐19 dermatolology immunomodulators Janus kinase inhibitors methotrexate systemic steroids [DOI] 10.1111/ajd.13313 PMC 바로가기 [Article Type] Review Article
A novel treatment for psoriatic arthritis: Janus kinase inhibitorsReview Article Published on 2020-04-202024-09-04 Journal: Chinese medical journal [Category] 대상포진, [키워드] drug treatment Janus kinase Janus kinase inhibitors psoriatic arthritis Tofacitinib [DOI] 10.1097/CM9.0000000000000711 PMC 바로가기 [Article Type] Review Article
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy바리시티닙을 투여받은 류마티스 관절염 환자의 폐렴구균 및 파상풍 백신 반응 평가: 장기 연장 시험 하위 연구 결과Research Article Published on 2019-04-182024-07-30 Journal: Arthritis Research & Therapy [Category] 파상풍, 폐렴구균 감염증, [키워드] DMARDs (biologics) Janus kinase inhibitors rheumatoid arthritis vaccination [DOI] 10.1186/s13075-019-1883-1 PMC 바로가기 [Article Type] Research Article